Review Article
Pharmacogenomics and pharmacogenetics are promising in development of a personalized treatment approach They are of paramount importance for basic immunology, for peptide based vaccine design (vaccinomics) drug monitoring in clinical setting and molecular pathophysiology of multifactorial diseases like cancer, tuberculosis, cardiac disorders, diabetes, asthma, HIV, etc constant monitoring of drug effi cacy. Though these medications signifi cantly reduce AIDS-related mortality [1] but their effi cacy is not only compromised by their toxicity, viral resistance, and nonadherence to treatment, but also by comorbidities lik hepatitis, diabetes, and cardiovascula disease.
The fi eld of pharmacogenomics strive to understand relationship between human genetic variations and response to treatment. [2] [3] [4] [5] [6] The relevance of pharmacogenomics to HIV therapeutics spans basic science, patient care, and public health disciplines.
Laboratory-based investigators use genomic techniques
to study viral pathogenesis to explore new targets for therapeutic intervention.
The potential for human genetic research to identify novel therapeutic targets is highlighted by previous studies of CCR5. This cellular chemokine receptor is required for infectivity of many HIV strains. [7] [8] [9] Soon after its role in HIV replication was elucidated, individuals were identifi ed who were highly resistant to HIV infection and lacked functional CCR5 as the result of a 32-bp deletion in the CCR5 gene but were otherwise healthy. [10] [11] [12] (APOBEC3G) [13] and tripartite motif '5a (TRIM5a)'. [14] The naturally occurring variants in these and associated genes which affect progression of HIV disease are potential intervention targets.
Progress in pharmacogenomics require access to Since 1986, the AACTG has enrolled 136,000 individuals into diverse prospective trials with well-defi ned entry criteria and on-study evaluations. To establish a usable DNA bank, a group of clinical researchers, genetic investigators, ethicists, statisticians, data managers, regulatory specialists, and community representatives worked in collaboration to develop AACTG Protocol A5128, which allows prospective study on stored DNA wher informed consent was obtained for other AACTG trials. [15] One challenge for the identifi cation of genetic associations in cohort studies is to defi ne control group with all relevant factors except the phenotype. an association between major histocompatibility complex alleles and hypersensitivity to abacavir. [17, 18] In patients exposed to abacavir in Perth, Australia, the presence of HLA-B*5701, HLA-DR7, and HLADQ3 had a positive predictive value of 100% and a negative predictive value of 97% for hypersensitivity [18] An association between hypersensitivity to abacavir and HLA-B*5701 and HLA-DR7 was confi rmed in patients in North America. [19] More-recent analyses have extended this association to include a polymorphism in Hsp70-Hom, a member of the heat shock protein family of chaperonins [19] HLA Class II allele DRB1*0101 has been associated with Nevirepineassocited hypersentivity. [20] HLA B*3505 allele has been a strong predictor for neverpine-induced skin adverse drug reactions in Thai HIV patients. [21] In nevirapine induced rash HIV-1 positive infected individuals from Mumbai, India a highly signifi cant association with HLA B35 an protection with HLA B7 is found. [22] The nonnucleoside reverse-transcriptase inhibitor efavirenz is one of the most widely prescribed antiretroviral medications [23, 24] but many recipients of efavirenz experience central nervous system side effects during the initial weeks of therapy. [24] Efavirenz is metabolized primarily by hepatic cytochrome P450 (CYP) 2B6 [25] and a large amount of interindividual variability in the amount of CYP2B6 in the liver has been reported [26] [27] [28] [29] as have functional differences between genetic variants. [28, [30] [31] [32] Specimens from the AACTG Human DNA Repository and associated data from clinical trials were used to show that a CYP2B6 exon 4 polymorphism that occurs more frequently in blacks than in whites is associated with ~3-fold higher plasma concentrations of efavirenz (P.000)) and with increased central nervous system side effects (P p.036). [33] Differences in the frequency of this polymorphism in different populations may explain the lower clearance of efavirenz noted in blacks. [34] [35] [36] Recently the importance of human CYP3A pharmacogenetics with the discovery of the Null allelle CYP3A4*20 have contributed in predicting effi cacy and/or toxicity in HIV patients. [37] The CYP3A4*1B polymorphism infl uences the pharmacokinetics of indinavir and to some extent its biochemical safety. [38] Tumor necrosis factor (TNF)-α has been implicated in the pathogenesis of lipodystroph [39] [40] [41] and TNF-α expression varies according to race and ethnicity. [42] Two research groups have reported relationships between antiretroviral-associated lipodystrophy and a TNF-α promoter polymorphism that may affect gene expression.
In 96 white patients in England, a TNF-α position 238 polymorphism was present only in subjects with lipodystrophy (P p .0)). [43, 44] These fi ndings support a role for TNF-α in the pathogenesis of lipoatrophy, this variant allele may simply be a marker for other genes with which it is linked, such as members of the major histocompatibility complex. [42] Bilirubin is the primary product of heme metabolism.
Its efficient elimination requires conjugation with glucuronic acid in a reaction catalyzed by hepatic UDPglucuronosyltransferase (UGT) 1A1. Approximately 5%-10% of individuals have decreased bilirubinconjugating activity that is caused by a TA insertion into the UGT1A1 promoter (Gilbert syndrome). [45, 46] The HIV inhibitors are substrates for P-glycoprotein, the multidrug effl ux pump encoded by MDR1 [47] and a frequent MDR1 exon 26 polymorphism has been associated with altered P-glycoprotein expression. [48] P-glycoprotein in the intestine, liver, and kidney is predicted to decrease oral bioavailability of these drugs and enhance their elimination. P-glycoprotein is also present in CD4 T cells, [49] and its expression in the brain limits entry of protease inhibitors. Importantly, a provocative report noted an association between the MDR1 exon 26
polymorphism, increases in CD4 T cells in response to antiretroviral therapy, and plasma concentrations of efavirenz and nelfi navir. [50] As pharmacogenomics moves from bench to bedside, most genotype-phenotype relationships will refl ect the combined infl uences of multiple genes and polymorphisms. The growing number of identified genetic associations will increase the impetus to make human genetic testing a routine part of HIV clinical care.
Prospective clinical trials will ultimately be needed to determine whether the use of human genetic testing to 
